Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study

被引：0
|
作者：
Liu, Yin
Zuo, Wen-Jia
Wang, Ruo-Xi
Wang, Zhong-Hua
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
基金：
上海市自然科学基金;
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Jamunarani Veeraraghavan
    Carolina Gutierrez
    Vidyalakshmi Sethunath
    Sepideh Mehravaran
    Mario Giuliano
    Martin J. Shea
    Tamika Mitchell
    Tao Wang
    Sarmistha Nanda
    Resel Pereira
    Robert Davis
    Kristina Goutsouliak
    Lanfang Qin
    Carmine De Angelis
    Irmina Diala
    Alshad S. Lalani
    Chandandeep Nagi
    Susan G. Hilsenbeck
    Mothaffar F. Rimawi
    C. Kent Osborne
    Rachel Schiff
    [J]. npj Breast Cancer, 7
  • [22] Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
    Fabbri, M. A.
    Botticelli, A.
    Omarini, C.
    Cretella, E.
    Fabi, A.
    Alesini, D.
    Pizzuti, L.
    Piesco, G.
    Vaccaro, A.
    Atzori, F.
    Piacentini, F.
    Moscetti, L.
    Orlandi, A.
    Sini, V.
    Mercanti, A.
    Framarino, M. L.
    Persano, M.
    Ceccherini, R.
    Ruggeri, E. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [23] Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China
    Deng, Weishang
    Hu, Jia
    Li, Mengting
    Yang, Sensen
    Xie, Zeyu
    Chen, Jisheng
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1117 - 1126
  • [24] Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama
    Rodriguez, Franklin Castillero
    Castillo-Fernandez, Omar
    Lim-Law, Maria
    Palacios, Cristiane Martin
    Montano, Lilian
    Benitez, Stephanie
    Samudio, Jaime
    [J]. BREAST CANCER MANAGEMENT, 2021, 10 (01)
  • [25] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [26] Neoadjuvant trastuzumab and pertuzumab in combination with anthracyclines in HER2-positive early breast cancer: real-world data on effect of body mass index in cardiac safety
    Simao, Diana
    Sardinha, Mariana
    Gil, Lucia
    Montenegro, Alexandra
    Mendes, Jose
    Fernandes, Leonor
    Winckler, Patricia
    Luz, Ricardo
    Oliveira, Sonia
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [27] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [28] Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
    Zhou, Meirong
    Wang, Shouman
    Wan, Nengbin
    Yuan, Songlin
    Hu, Xiongqiang
    Zhou, Wei
    Qing, Bohua
    Liu, Mingwen
    Sun, Weihua
    Fan, Peizhi
    Wang, Jianguo
    Cao, Hong
    Xu, Haifan
    Dai, Bin
    Tang, Peizhi
    Qian, Liyuan
    Zhao, Xi
    Xiao, Jun
    Zhou, Huaiying
    Hu, Jinhui
    Ding, Li
    Tripodi, Domenico
    Zdenkowski, Nicholas
    O'Keefe, Thomas J.
    Sanchez, Alejandro Martin
    Chen, Li
    Zhang, Ping
    Xu, Feng
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [29] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [30] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
12345